Please assess the completion status of the following clinical trial:

Trial Title: L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of breast cancer~  * Metastatic disease~* Scheduled to receive ≥ 1 of the following chemotherapy drugs:~  * Paclitaxel~ * Docetaxel~ * Capecitabine~ * Gemcitabine hydrochloride~    * Concurrent enrollment in the University of Minnesota study Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors (Human Subjects Code 0508M72989) required~ * Albumin-bound paclitaxel (Abraxane)~ * Doxorubicin hydrochloride~PATIENT CHARACTERISTICS:~* Life expectancy ≥ 6 months~* Serum creatinine \< 2.0 mg/dL~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No history of seizures~* No uncontrolled hypertension~* No history of stroke~* No malabsorption syndrome~* No cognitive impairment~* No history of psychiatric disability affecting informed consent or compliance with drug intake~* Able to take oral medication~* Able to complete questionnaire(s) alone or with assistance~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No concurrent warfarin~* No concurrent radiotherapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral L-carnitine L-tartrate twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive oral placebo twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).